Peregrine's Bavituximab has high success rate in animal testing

An antibody equivalent to Peregrine's (PPHM) Bavituximab immunotherapy eradicated tumors in two-thirds of rats with non-small cell lung cancer when combined with radiation in a trial, with 100% of the animals surviving after 184 days.

In rats that received just radiation, the survival rate was 43%, while it was 12.5% in untreated animals.

Shares are +7.6%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs